Biomarkers for Oncology
JH · Effective Oct 1, 2015
9 active Medicare policies list N40.0, and 9 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JL · Effective Apr 24, 2025
National · Effective Nov 1, 2025
J6 · Effective Oct 1, 2024
9 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of N40.0 |
|---|---|---|
| Benign Prostatic Hyperplasia | Feb 8, 2024 | Covered |
| Botulinum Toxin | Jan 1, 2024 | Covered |
| Cryoablation | Dec 5, 2023 | Covered |
| Gonadotropin-Releasing Hormone Analogs and Antagonists | Jul 14, 2023 | Covered |
| Intraoperative Neurophysiological Monitoring | Oct 26, 2023 | Covered |
| Prostate Cancer Screening | Jul 14, 2023 | Covered |
| Policy | Effective | Status of N40.0 |
|---|---|---|
| Outpatient Urine Culture | Jan 6, 2026 | Covered |
| Prostate Specific Antigen Testing | Apr 15, 2026 | Covered |
| Transrectal Ultrasonography | Apr 15, 2026 | Covered |